Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANF-RHO vs Neulasta in Breast Cancer with Chemotherapy-Induced Neutropenia
NCT03559387Phase 2Terminated
- Sponsor
- Prolong Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of ANF-RHO in neutropenia, sponsored by Prolong Pharmaceuticals. Started Aug 2017; status: terminated.
02
Drugs
ANF-RHO
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03559387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559387.